-
Cancer – A Costly Diagnosis?
Stories of the financial impact of cancer.
-
Why the Drug Industry has to Change
A small group of Dutch professionals take matters into their own hands and show how things can be improved.
-
Cancer Patients Crippled by Financial Costs and Anxiety as They fight for Survival, Charity Warns Opens in a new window)
The Irish Cancer Society has claimed hard-pressed patients and their families are “under siege”.
-
NICE Annual Report 2018/19
-
Government Must Reduce ‘Huge Financial Strain’ on Cancer Patients Opens in a new window)
Irish Cancer Society says patients and families are ‘under siege’ in budget submission.
-
New Drugs: Where Did We Go Wrong And What Can We Do Better?
More than half of new drugs entering the German healthcare system have not been shown to add benefit.
-
NICE Restores Parity Between Alnylam and Akcea on Rare Disease Opens in a new window)
Drugmaker Alnylam has offered a confidential discount on the list price of its rare disease drug to secure NICE’s backing for use on the NHS in England.
-
A Review of ATMP HTA Reports
European HTA recommendations for ATMPs available as of June 2019.
-
What the U.S. can Learn From Germany on Drug Prices Opens in a new window)
While German-style drug pricing would be highly disruptive to the U.S. health system, the country's use of private insurers and its resistance to outright price-setting provides an illuminating case study.
-
Getting Ready
Recommendations for Timely Access to ATMPs in Europe
-
Doctors in Uproar Over Medication That Tripled in Price Opens in a new window)
Psychiatrists and patients in Belgium are up in arms over the decision by British pharmaceutical company Essential Pharma to increase the price of a drug used for the treatment of people with bipolar disorder.
-
Could a UK-US Trade Deal Make Pharmaceuticals Pricier?
What sort of impact could trade deal compromises have on the price of pharmaceuticals?
-
AstraZeneca boss calls for NHS drug approval shake-up Opens in a new window)
AstraZeneca CEO calls for a comprehensive review of how NICE values innovative medicines - after NICE refused to pay for one of its most important cancer medications.
-
NICE Approves CDF Funding for Sanofi's Libtayo Opens in a new window)
Sanofi has a managed access agreement (data collection arrangement including a commercial access agreement) which makes the drug available to the NHS with a discount.
-
How Two Americans Fared with the German Health Care System Opens in a new window)
Germany has the oldest health care system in the world. And it's working. Is Germany's health care system a model for the U.S.?
